Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?

The link between metabolic syndrome (MetS) and sarcopenia has not been extensively studied, but it is evident that they share several common features. Crucial mechanisms involved in sarcopenia-nonalcoholic fatty liver disease (NAFLD) interplay are based on effects of insulin resistance, chronic infl...

Full description

Saved in:
Bibliographic Details
Main Authors: Ivana Mikolasevic, Tajana Pavic, Tajana Filipec Kanizaj, Darija Vranesic Bender, Viktor Domislovic, Zeljko Krznaric
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Canadian Journal of Gastroenterology and Hepatology
Online Access:http://dx.doi.org/10.1155/2020/8859719
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832563907876618240
author Ivana Mikolasevic
Tajana Pavic
Tajana Filipec Kanizaj
Darija Vranesic Bender
Viktor Domislovic
Zeljko Krznaric
author_facet Ivana Mikolasevic
Tajana Pavic
Tajana Filipec Kanizaj
Darija Vranesic Bender
Viktor Domislovic
Zeljko Krznaric
author_sort Ivana Mikolasevic
collection DOAJ
description The link between metabolic syndrome (MetS) and sarcopenia has not been extensively studied, but it is evident that they share several common features. Crucial mechanisms involved in sarcopenia-nonalcoholic fatty liver disease (NAFLD) interplay are based on effects of insulin resistance, chronic inflammation, oxidative stress, and crosstalk between organs by secretion of cytokines (hepatokines, adipokines, and myokines). Currently, published studies confirm the association of sarcopenia with the degree of NAFLD defined by liver histology. However, prospective studies that will give us information regarding the causal effect of NAFLD and sarcopenia are still needed. Furthermore, there is a need for a patient-friendly, noninvasive, low-cost method for detection of loss of skeletal muscle mass, strength, and physical performance in the context of NAFLD. Moreover, potential treatment strategies such as physical exercise and nutritional supplementation, that are usually a part of management of sarcopenia, should also be investigated in NAFLD patients, especially given the fact that for now, we do not have a good treatment option for NAFLD. Therefore, future investigations should combine studies on NAFLD and sarcopenia in terms of physical activity and nutritional interventions such as vitamin D supplementation. This review aims to report recent evidence concerning the links between sarcopenia and NAFLD and methods to assess sarcopenia.
format Article
id doaj-art-59654e420c7649dcbb5b18c59205dd46
institution Kabale University
issn 2291-2797
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Canadian Journal of Gastroenterology and Hepatology
spelling doaj-art-59654e420c7649dcbb5b18c59205dd462025-02-03T01:12:14ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27972020-01-01202010.1155/2020/88597198859719Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?Ivana Mikolasevic0Tajana Pavic1Tajana Filipec Kanizaj2Darija Vranesic Bender3Viktor Domislovic4Zeljko Krznaric5Department of GastroenterologyDepartment of Internal MedicineDepartment of GastroenterologyUniversity Hospital Centre ZagrebDepartment for Gastroenterology and HepatologySchool of MedicineThe link between metabolic syndrome (MetS) and sarcopenia has not been extensively studied, but it is evident that they share several common features. Crucial mechanisms involved in sarcopenia-nonalcoholic fatty liver disease (NAFLD) interplay are based on effects of insulin resistance, chronic inflammation, oxidative stress, and crosstalk between organs by secretion of cytokines (hepatokines, adipokines, and myokines). Currently, published studies confirm the association of sarcopenia with the degree of NAFLD defined by liver histology. However, prospective studies that will give us information regarding the causal effect of NAFLD and sarcopenia are still needed. Furthermore, there is a need for a patient-friendly, noninvasive, low-cost method for detection of loss of skeletal muscle mass, strength, and physical performance in the context of NAFLD. Moreover, potential treatment strategies such as physical exercise and nutritional supplementation, that are usually a part of management of sarcopenia, should also be investigated in NAFLD patients, especially given the fact that for now, we do not have a good treatment option for NAFLD. Therefore, future investigations should combine studies on NAFLD and sarcopenia in terms of physical activity and nutritional interventions such as vitamin D supplementation. This review aims to report recent evidence concerning the links between sarcopenia and NAFLD and methods to assess sarcopenia.http://dx.doi.org/10.1155/2020/8859719
spellingShingle Ivana Mikolasevic
Tajana Pavic
Tajana Filipec Kanizaj
Darija Vranesic Bender
Viktor Domislovic
Zeljko Krznaric
Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?
Canadian Journal of Gastroenterology and Hepatology
title Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?
title_full Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?
title_fullStr Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?
title_full_unstemmed Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?
title_short Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?
title_sort nonalcoholic fatty liver disease and sarcopenia where do we stand
url http://dx.doi.org/10.1155/2020/8859719
work_keys_str_mv AT ivanamikolasevic nonalcoholicfattyliverdiseaseandsarcopeniawheredowestand
AT tajanapavic nonalcoholicfattyliverdiseaseandsarcopeniawheredowestand
AT tajanafilipeckanizaj nonalcoholicfattyliverdiseaseandsarcopeniawheredowestand
AT darijavranesicbender nonalcoholicfattyliverdiseaseandsarcopeniawheredowestand
AT viktordomislovic nonalcoholicfattyliverdiseaseandsarcopeniawheredowestand
AT zeljkokrznaric nonalcoholicfattyliverdiseaseandsarcopeniawheredowestand